Cyclacel Pharmaceuticals Stock Forecast, Price & News

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

Is Cyclacel Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals or view top-rated stocks.

How has Cyclacel Pharmaceuticals' stock price been impacted by Coronavirus?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYCC shares have increased by 561.2% and is now trading at $3.57.
View which stocks have been most impacted by COVID-19.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cyclacel Pharmaceuticals.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.16. During the same period last year, the business posted ($0.47) EPS.
View Cyclacel Pharmaceuticals' earnings history.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CYCC?

2 equities research analysts have issued twelve-month price objectives for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:

• Spiro Rombotis, President, Chief Executive Officer & Director
• Paul McBarron, Secretary, Chief Operating & Financial Officer
• Mark Kirschbaum, Chief Medical Officer & Senior Vice President
• Amartya Basu, Senior Director-Business Development

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Some companies that are related to Cyclacel Pharmaceuticals include Galectin Therapeutics (GALT), Satsuma Pharmaceuticals (STSA), Oncternal Therapeutics (ONCT), Opiant Pharmaceuticals (OPNT), Xeris Pharmaceuticals (XERS), Zynerba Pharmaceuticals (ZYNE), NervGen Pharma (NGENF), NuCana (NCNA), Vascular Biogenics (VBLT), Tyme Technologies (TYME), Equillium (EQ), Enlivex Therapeutics (ENLV), BioVie (BIVI), scPharmaceuticals (SCPH) and ProMetic Life Sciences (PFSCF).
View all of CYCC's competitors.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Tri Locum Partners LP (5.66%), Affinity Asset Advisors LLC (4.33%), Two Sigma Advisers LP (1.32%), Morgan Stanley (1.22%), Pura Vida Investments LLC (1.14%) and Geode Capital Management LLC (0.64%). Company insiders that own Cyclacel Pharmaceuticals stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends for Cyclacel Pharmaceuticals.

Which major investors are selling Cyclacel Pharmaceuticals stock?

CYCC stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Raymond James Financial Services Advisors Inc., Two Sigma Investments LP, and Morgan Stanley.
View insider buying and selling activity for Cyclacel Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was purchased by a variety of institutional investors in the last quarter, including Tri Locum Partners LP, Two Sigma Advisers LP, Citadel Advisors LLC, Affinity Asset Advisors LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, and NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $3.57.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals has a market capitalization of $35.61 million and generates $150 thousand in revenue each year. The biotechnology company earns $-8.44 million in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

Cyclacel Pharmaceuticals employs 2,018 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

Where are Cyclacel Pharmaceuticals' headquarters?

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at (908) 517-7330, via email at [email protected], or via fax at 866-271-3466.